In alphabetical order:
Biogen
Exhibition, stand number: B0.01
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
www.biogen.com
Boehringer Ingelheim
Exhibition, stand number: B0.07
At Boehringer Ingelheim, we hope to alleviate the burden on people living with serious mental illnesses, their care partners, loved ones, and society. To do this, we have made a long-term commitment to invest in research with the aspiration of redefining mental healthcare in partnership with multiple stakeholders and innovative partners. Our ambition is to create a deeper understanding of the drivers of serious mental illnesses and to provide highly effective therapies for those living with these conditions. More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com.
Brain Congress
Exhibition, stand numbers: B0.23
The Congress on Brain, Behavior, and Emotions is a premier scientific event that annually brings together over 6000 participants. The congress provides an interdisciplinary platform for healthcare professionals, researchers, and academics to engage with the latest advances in neuroscience, psychiatry, psychology, and related fields, fostering continuing education and the translation of scientific discoveries into clinical practice.
https://braincongress.com.br/
Bristol Myers Squibb
Exhibition, stand number: B0.06
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are motivated by the power of science, with a legacy of pursuing bold science across oncology, hematology, cardiovascular, immunology and neuroscience. We’re accelerating the development of new medicines with differentiated research platforms and leading technology to define what’s possible for the future of medicine and the patients we serve. https://www.bms.com/
CINP – International College of Neuropsychopharmacology
Exhibition, stand number: B0.24
The International College of Neuropsychopharmacology (CINP) is the oldest organization in the world devoted to studying how medicines affect the brain and the mind. It is a truly global community which connects researchers, clinicians and healthcare professionals, promoting the understanding, prevention and treatment of psychiatric and neurological disorders and enabling clinicians to hear about the latest advances in research and novel treatments, and researchers to learn about new clinical needs and challenges.
Key activities include the organisation of international scientific congresses, educational programmes, webinars and workshops; the dissemination of cutting-edge scientific knowledge; the development of collaborative research initiatives; and the support of early-career scientists through mentoring, training and travel grant programmes.
CINP has also played an important role in fostering international collaboration, supporting scientific excellence, and promoting evidence-based approaches to the treatment of psychiatric disorders worldwide.
It stated mission is as follows: Advancing worldwide neuroscience and education for brain and mental health.
www.cinp.org
EUFAMI
Exhibition, stand number: B0.28
EUFAMI was founded in 1992 after a congress, which took place in 1990 in De Haan, Belgium, where carers from all over Europe shared their experiences of helplessness and frustration when living with severe mental illness. They resolved to work together to help both themselves and the people they cared for. EUFAMI is a democratic organisation, registered in Belgium as an international non-profit organisation. We have an ongoing commitment to improving care and welfare for people affected by mental illness. We also enable our member organisations to act jointly at a European Level, combining their efforts and sharing experience.
www.eufami.org
European Brain Council (EBC)
Exhibition, stand number: B0.27
The European Brain Council (EBC) is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners. A non-profit organisation based in Brussels, its main mission is to promote brain research with the ultimate goal of improving the lives of the millions of Europeans living with brain conditions, mental and neurological alike. EBC maintains a strong interaction with the European Institutions to build strong health policies, raising awareness and improving knowledge of the brain and the repercussions of neurological and mental health conditions on society as a whole.
https://www.braincouncil.eu/
European Psychiatric Association (EPA)
Exhibition, stand number: B0.20
With active individual members in as many as 88 countries and 47 National Psychiatric Association Members who represent more than 80 000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. The EPA’s activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. The EPA deals with psychiatry and its related disciplines and focuses on the improvement of care for the mentally ill as well as on the development of professional excellence.
https://www.europsy.net/
FENS - The Federation of European Neuroscience Societies
Exhibition, stand number: B0.26
FENS is the main organisation for neuroscience in Europe based in Brussels, Belgium. It currently represents and serves 44 neuroscience societies across 33 European countries and more than 25,000 scientists. Its main mission is to support and promote neuroscience research in Europe and beyond. Its activities operate across four main impact areas: advancing neuroscience research; facilitating knowledge exchange; empowering community; and investing in the future. In addition, FENS emphasises the importance of its core values – credibility, inclusivity, and sustainability – in all its activities, helping to ensure they are representative of the diverse neuroscience community and reinforcing responsible research.
https://www.fens.org/
GAMIAN-Europe
Exhibition, stand number: B0.33
Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe), is a non-profit, patient-driven pan-European organisation, representing and advocating the interests and rights of persons affected by mental ill-health.
https://www.gamian.eu/
GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).
https://www.ghres.com/
H. Lundbeck A/S
Exhibition, stand number: B0.08
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.
Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
www.lundbeck.com
Nanjing Healed Gene Biotechnology Co., Ltd.
Exhibition, stand numbers: B0.11
Nanjing Healed Gene Biotechnology Co., Ltd. is partially owned by Jiangsu Southeast University Assets Management and mainly manufacture depression tests. Healed Gene Depression Test (CE certified) ✅ Detects depression (yes/no) ✅ Classifies its severity (normal, mild to moderate, or severe) ✅ Evaluates treatment efficacy (SSRI/SNRI, TMS, ECT, Ketamine,etc ) The test details are as below, Test sample: 3ml blood or 3ml saliva Depression biomarkers: 4 Circular RNA genes Test method: PCR process in laboratory. It offers measurable evidence that doctors can share with their patients to demonstrate a reduction in depression scores following treatment—thereby reinforcing treatment effectiveness.
https://www.healedgene.com/
Neuroscience based Nomenclature (NbN)
Exhibition, stand number: B0.22
Transitioning from indication-based to pharmacology-driven nomenclature promotes informed, rational, evidence-based prescribing in psychiatry. It helps reduce stigma by emphasizing the neuroscience rather than disease labels. A pharmacologically driven system also enhances teaching and understanding of drug–target interactions. The Neuroscience-based Nomenclature (NbN) initiative, led by an international collaboration of neuropsychopharmacology organizations, has been at the forefront of this effort.
www.nbn.science
Neurotorium
Exhibition, stand number: B0.21
Neurotorium.org is a non-commercial, non-profit educational platform with the mission to improve awareness and knowledge of the brain and its diseases. We provide unbiased, freely available online educational content created for clinicians, educators, and anyone interested in learning more about the brain. All our educational material is developed, reviewed, and regularly updated by leading experts within the fields of psychiatry, neurology, and neuroscience. Neurotorium is founded by the Lundbeck Foundation.
https://neurotorium.org/
Otsuka Pharmaceutical Development & Commercialization, Inc.
Exhibition, stand number: B0.09
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. are the US-based indirect subsidiaries of the global healthcare company Otsuka Pharmaceutical Co. Ltd with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka’s US companies share a deep commitment to the development and commercialization of innovative products in the spaces of neuroscience, nephrology, and immunology. At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere. https://www.otsuka-us.com
Otsuka Pharmaceutical Europe Ltd.
Otsuka Pharmaceutical Co. Ltd., is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Our employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on psychiatric and neurologic disorders, nephrology and immunology, haemato-oncology, and digital therapeutics.
https://www.otsuka-europe.com/otsuka-in-europe
Resilience Psychiatry
Exhibition, stand numbers: B0.12
Resilience Care is a leading player in medical remote monitoring and a key partner in clinical research. Founded in France in 2021, the company has remained committed to one core mission: to provide better care for patients. Resilience Care delivers remote monitoring solutions in oncology, immunology, and psychiatry, currently used in routine care for over 37,000 patients across more than 220 healthcare facilities, as well as in over 20 academic and industry-sponsored clinical studies. By harnessing the power of data to support care and therapeutic innovation, Resilience Care aims to make personalized medicine accessible to every patient.
With Resilience Psychiatry, the company offers a remote monitoring medical device (CE class IIa certified) designed for patients with mood disorders. The solution enables periodic and longitudinal patient monitoring. Resilience Psychiatry includes a monitoring platform for healthcare professionals enabling them to evaluate treatment effectiveness and improve patient follow-up through the collection of PRO data, as well as a mobile application allowing patients to measure their psychological and physical symptoms and access appropriate resources.
https://www.resilience.care/healthcare-providers/psychiatry
Takeda Pharmaceuticals International AG
Exhibition, stand numbers: B0.02
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.
https://www.takeda.com/
The Lundbeck Foundation
The Brain Prize
The Lundbeck Foundation is an enterprise foundation whose purpose is to create powerful ripple effects that bring discoveries to lives through investing actively in business and science at the frontiers of their fields.
The world’s largest brain research prize is awarded annually by the Lundbeck Foundation. Each year, they award 10 million DKK (approx. 1,3 million EUR) to one or more neuroscientists who have made a ground-breaking impact on brain research. The Brain Prize was first awarded in 2011 and has so far honoured 51 scientists from 11 different countries.
www.brainprize.org
Wisepress Medical Bookshop
Exhibition, stand number: B0.29
Wisepress.com is Europe’s leading conference bookseller. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on X @WisepressBooks.
https://www.wisepress.com/
